Last reviewed · How we verify
TRI102
TRI102 is a medication that works by inhibiting the reuptake of serotonin and norepinephrine.
TRI102 is a medication that works by inhibiting the reuptake of serotonin and norepinephrine. Used for Major depressive disorder.
At a glance
| Generic name | TRI102 |
|---|---|
| Also known as | amphetamine extended-release oral suspension |
| Sponsor | Tris Pharma, Inc. |
| Drug class | Serotonin-norepinephrine reuptake inhibitor (SNRI) |
| Modality | Small molecule |
| Therapeutic area | Depression |
| Phase | Phase 3 |
Mechanism of action
This action increases the levels of these neurotransmitters in the brain, which can help improve mood and reduce symptoms of depression. TRI102 is a serotonin-norepinephrine reuptake inhibitor (SNRI).
Approved indications
- Major depressive disorder
Common side effects
- Nausea
- Headache
- Dizziness
- Fatigue
- Insomnia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRI102 CI brief — competitive landscape report
- TRI102 updates RSS · CI watch RSS
- Tris Pharma, Inc. portfolio CI